2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W775346
    Delta8-THC acetate 23050-54-6 98%
    Delta8-THC acetate (Delta8-tetrahydrocannabinol) is a psychoactive phytocannabinoid, that binds to cannabinoid receptor 1 (CB1 receptor), and exhibits anti-nausea, appetite-stimulating, and anti-inflammatory activities. Delta8-THC acetate exhibits probably neuroprotective efficacy and can be used in anti-anxiety and antidepressant research.
    Delta8-THC acetate
  • HY-W775348
    Tetrahydrocannabiphorol 54763-99-4 98%
    Tetrahydrocannabiphorol (THCP) is a phytocannabinoid.
    Tetrahydrocannabiphorol
  • HY-W777166
    Aprepitant-13C2,d2 (Major) 1217676-37-3 98%
    Aprepitant-13C2,d2 (Major) (MK-0869-13C2,d2) is 13C labeled Aprepitant. Aprepitant (MK-0869) is a selective and high-affinity neurokinin 1 receptor antagonist with a Kd of 86 pM.
    Aprepitant-13C2,d2 (Major)
  • HY-W778574
    BAPTA tetracesium 480436-84-8 98%
    BAPTA tetracesium is a selective and cell-impermeant chelator for calcium. BAPTA tetracesium has high selectivity against magnesium and calcium. BAPTA tetracesium can also inhibit phospholipase C activity independently of their role as Ca2+ chelators.
    BAPTA tetracesium
  • HY-W781963
    7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one 62659-65-8 98%
    7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one is a metabolite of Flubromazepam.
    7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one
  • HY-W783639
    Bzo-poxizid 1048973-64-3 98%
    Bzo-poxizid is a synthetic cannabinoid that is a psychoactive substance.
    Bzo-poxizid
  • HY-W792513
    WAY-620147 515866-67-8 98.0%
    WAY-620147 (compound 6) is an N-(2-morpholinoethyl)nicotinamide derivative that inhibits monoamine oxidase (Monoamine Oxidase). WAY-620147 inhibits MAO-A and MAO-B with IC50s of 26 μM and 55 μM, respectively.
    WAY-620147
  • HY-W835723
    1-(2,6-Dimethoxyphenyl)-3-(4-hydroxyphenyl)propan-1-one 221696-69-1 98.75%
    1-(2,6-Dimethoxyphenyl)-3-(4-hydroxyphenyl)propan-1-one is a phenolic compound derived from Dracaena cochinchinensis that exhibits antioxidant, antimicrobial, antiviral, hemostatic, antithrombotic, anti-inflammatory activities, and protects myocardial cells.
    1-(2,6-Dimethoxyphenyl)-3-(4-hydroxyphenyl)propan-1-one
  • HY-W839261
    Tyrosine kinase-IN-9 370854-75-4 98%
    Tyrosine kinase-IN-9 (Compound B) is the inhibitor for c-Abl. Tyrosine kinase-IN-9 can be used in research of neurodegenerative diseases including Alzheimer’s and Parkinson’s disease.
    Tyrosine kinase-IN-9
  • HY-W839383
    2,3-Diphenylquinoxaline-6-sulphonamide 380347-87-5 98%
    2,3-Diphenylquinoxaline-6-sulphonamide exhibits potential antibacterial, analgesic, and anti-inflammatory properties.
    2,3-Diphenylquinoxaline-6-sulphonamide
  • HY-W840382
    CK1δ-IN-8 438018-70-3 98%
    CK1δ-IN-8 (Compound 429) is a CK1δ inhibitor that can be used in Alzheimer's disease research.
    CK1δ-IN-8
  • HY-W844543
    Protein kinase inhibitor 12 721964-48-3 98%
    Protein Kinase Inhibitor 12 (compound 1-91) is a triazolopyridazine derivative and protein kinase inhibitor that can be utilized in research related to diseases associated with protein kinases.
    Protein kinase inhibitor 12
  • HY-W922811
    DL-Willardiine 19772-76-0 98%
    DL-Willardiine is an AMPA antagonist with an IC50 of 2 μM. DL-Willardiine can be utilized in psychotropic cccccc research.
    DL-Willardiine
  • HY-W931056
    AMG-628 862269-93-0 98%
    AMG-628 is an orally active inhibitor for TRPV1, that inhibits Capsaicin (HY-10448) or acid (pH 5)-induced Ca2+ influx into TRPV1- expressing CHO cell with IC50 of 4.9 and 3.1 nM. AMG-628 exhibits analgesic activity in Capsaicin (HY-10448)-induced rat model, and exhibits a half-life of 2.4 h in rats.
    AMG-628
  • HY-W975966
    CPDT 14085-33-7 98%
    CPDT is an orally active and highly potent inducer of phase 2 enzymes and an activator of Nrf2. The activities of key phase 2 enzymes, including glutathione S-transferase, NAD(P)H:quinone:oxidoreductase 1 and glutamate cysteine synthetase, and levels of glutathione were elevated by CPDT in rat bladder in vivo and in cultured bladder cells in vitro[2].
    CPDT
  • HY-Y0258AR
    Benzocaine (hydrochloride) (Standard) 23239-88-5 98%
    Benzocaine hydrochloride (Standard) is an analytical standard of Benzocaine hydrochloride (HY-Y0258A). This product is intended for research and analytical applications. Benzocaine hydrochloride is an orally active local anesthetic. Benzocaine hydrochloride non-competitively inhibits the binding of Ca-ATPase to Ca2+, with a IC50 of 47.1 mM. Benzocaine hydrochloride exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine hydrochloride induces methemoglobinemia in various experimental animals.
    Benzocaine (hydrochloride) (Standard)
  • HY-100228AR
    SKF89976A hydrochloride (Standard) 85375-15-1
    SKF89976A (hydrochloride) (Standard) is the analytical standard of SKF89976A (hydrochloride) (HY-100228A). This product is intended for research and analytical applications. SKF89976A hydrochloride is a selective GABA transporter (GAT-1) inhibitor with IC50s of 0.28 μM, 137.34 μM and 202.8 μM for GAT-1, GAT-2 and GAT-3 in CHO cells, respectively.
    SKF89976A hydrochloride (Standard)
  • HY-100234AR
    DREADD agonist 21 dihydrochloride (Standard) 2250025-92-2 98%
    DREADD agonist 21 (dihydrochloride) (Standard) is the analytical standard of DREADD agonist 21 (dihydrochloride) (HY-100234A). This product is intended for research and analytical applications. DREADD agonist 21 dihydrochloride is a potent human muscarinic acetylcholine M3 receptors (hM3Dq) agonist (EC50=1.7 nM).
    DREADD agonist 21 dihydrochloride (Standard)
  • HY-100347AR
    SRI-011381 hydrochloride (Standard) 2070014-88-7 98%
    SRI-011381 (hydrochloride) (Standard) is the analytical standard of SRI-011381 (hydrochloride) (HY-100347A). This product is intended for research and analytical applications. SRI-011381 hydrochloride is an orally active TGF-β signaling agonist, exhibits neuroprotective effects.
    SRI-011381 hydrochloride (Standard)
  • HY-100369AR
    DMCM hydrochloride (Standard) 1215833-62-7 98%
    DMCM (hydrochloride) (Standard) is the analytical standard of DMCM (hydrochloride). This product is intended for research and analytical applications. DMCM hydrochloride is a nonselective full inverse agonist of benzodiazepine. DMCM shows bnding afinity at human recombinant GABAA αxβ3γ2 receptor subtypes with Kis of 10 nM, 13 nM, 7.5 nM, 2.2 nM for α1, α2, α3, and α5 ?receptors, respectively.
    DMCM hydrochloride (Standard)
Cat. No. Product Name / Synonyms Application Reactivity